Abstract
This programme has included 177 patients and shown that glipizide is an effective high-potency oral sulphonylurea, which provides an overall satisfactory control rate of 73.7% and a 45% satisfactory control rate in diabetics who have been failures on previous treatment. These comparative studies have shown the efficacy of glipizide to be at least equal to that of glibenclamide.
It has been shown that the average daily dose of glipizide is about 12.3 mg/ day with a range of from 1.25 mg/day to the maximum dose of 30 mg/day.
The toleration and safety of glipizide is excellent; furthermore, no effect on the liver or renal function was detected and neither ophthalmological roentgenological nor electrocardiographical abnormalities were observed.
Get full access to this article
View all access options for this article.